Core Insights - Scilex Holding Company has successfully closed the second tranche of its strategic investment in Datavault AI, acquiring shares valued at approximately $583.3 million based on the closing price of Datavault's common stock [1][5]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [3][4]. - The company has several commercial products, including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [3][4]. Product Development - Scilex has three product candidates in development: - SP-102, a viscous gel for lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [4]. - SP-103, a next-generation lidocaine topical system for acute pain, which has recently completed a Phase 2 trial [4]. - SP-104, a low-dose naltrexone for fibromyalgia treatment, is also under development [6]. Strategic Investment - The strategic investment in Datavault AI involves the purchase of a pre-funded warrant for 263,914,094 shares of Datavault AI common stock, with the transaction being approved by Datavault's stockholders [5]. - Both companies plan to enhance collaboration to drive growth in Real World Asset tokenization starting in 2026 [5]. Datavault AI Overview - Datavault AI specializes in AI-driven data experiences and asset monetization, offering solutions across various industries, including biotech, fintech, and healthcare [7]. - The company’s platform includes technologies for audio transmission and high-performance computing, enabling secure monetization and data analytics [7].

Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, issuing a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to provide growth capital to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, and support platform expansion [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, which includes a nonrefundable upfront license fee totaling $10 million and potential sales milestone payments of up to $2.55 billion [3][4] Financial Details - The initial tranche of Scilex's investment was closed on September 26, 2025, valued at approximately $8 million in Bitcoin [1][8] - The second tranche involves a purchase of approximately 1,237.6 Bitcoin, reflecting a significant investment in Datavault's future growth [1][8] - Scilex will pay the upfront license fee in four equal installments of $2.5 million, with the first payment due by December 31, 2025 [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault AI CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company's technology suite includes patented technologies for audio transmission and high-performance computing solutions [6][7]

Core Insights - Datavault AI has successfully closed the second tranche of equity financing with Scilex Holding Company, involving the issuance of a pre-funded warrant for approximately 263.91 million shares in exchange for about 1,237.6 Bitcoin [1][8] - The strategic investment aims to enhance Datavault's digital asset reserves, accelerate supercomputing infrastructure, support platform expansion, and create new revenue streams [2] - Datavault has granted Scilex an exclusive worldwide license for its AI-driven technology tailored for the biotech and biopharma industry, enabling the creation of a Biotech Exchange platform [3] Financial Details - The second tranche follows an initial investment in September 2025, valued at approximately $8 million in Bitcoin [1] - Under the licensing agreement, Datavault will receive a nonrefundable upfront license fee of $2.5 million in four installments, totaling $10 million, and is eligible for sales milestone payments up to $2.55 billion [4] Leadership Commentary - Scilex CEO Henry Ji expressed confidence in the collaboration, highlighting the alignment of Datavault's technologies with the biotech sector's needs for advanced data analytics and supercomputing power [5] - Datavault CEO Nathanial Bradley welcomed Scilex as a major stockholder, emphasizing the shared vision for leveraging digital assets to capture market share in the biotech sector [5] Company Overview - Datavault AI specializes in AI-driven data experiences and asset monetization in the Web 3.0 environment, offering solutions across various industries including biotech, fintech, and healthcare [6][7] - The company’s technology suite includes customizable AI and Machine Learning automation, detailed analytics, and marketing automation [9]

Core Viewpoint - Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds, which will be used for working capital and general corporate purposes [1][4]. Group 1: Warrants and Proceeds - The company exercised two sets of existing warrants, totaling 904,396 shares, at a reduced exercise price of $22.51 per share [1]. - The April 2024 Warrants were originally priced at $38.50 per share, while the December 2024 Warrants had an exercise price of $22.72 per share [1]. - The gross proceeds from the exercise of these warrants were approximately $20.3 million before deducting fees and expenses [1]. Group 2: New Warrant Issuance - In exchange for the immediate cash exercise of the existing warrants, the company issued a new unregistered warrant for 1,356,594 shares at an exercise price of $29.00 per share, which is exercisable immediately and has a five-year term [3]. - The new warrant was offered in a private placement under Section 4(a)(2) of the Securities Act and Regulation D [5]. Group 3: Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [8]. - The company's commercial products include ZTlido, ELYXYB, and Gloperba, which target significant unmet medical needs [9][10]. - Scilex has three product candidates in development, including SP-102, SP-103, and SP-104, which are aimed at various pain management indications [10].

PALO ALTO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of (i) 428,572 shares of common ...

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39852 Scilex Holding Company (Exact Name of Registrant as Specified in Its Charter) Delaware 92-1062542 (State or Other Jurisdiction of I ...

Core Points - Datavault AI Inc. has announced a special distribution of Dream Bowl Draft meme coins to eligible shareholders of Scilex Holding Company and Datavault AI, with a record date set for November 25, 2025 [1][3] - Each shareholder will receive one exclusive commemorative digital collectible for every share held, which includes features such as proof of ownership and embedded ticket information [3] - The ex-dividend date for DVLT and SCLX common stock is November 24, 2025, and short sellers must return borrowed shares by this date to avoid a "naked short" status [2] Company Overview - Datavault AI leads the development of AI-driven data experiences, asset valuation, and monetization in the Web 3.0 environment, integrating acoustic science and data science into a comprehensive cloud platform [4] - The company offers solutions across various industries, including sports entertainment, biotech, education, fintech, real estate, healthcare, and energy, utilizing patented technologies for high-performance computing [4] - Datavault AI's technology suite supports customizable features, including AI and machine learning automation, third-party integration, and marketing automation services [4]

Core Viewpoint - Scilex Holding Company announced the distribution of a Dream Bowl 2026 Meme Coin to eligible stockholders in collaboration with Datavault AI, with a record date set for November 25, 2025, and an ex-dividend date of November 24, 2025 [1][2]. Company Overview - Scilex is focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [6][8]. - The company has commercial products including ZTlido® for neuropathic pain, ELYXYB® for acute migraine treatment, and Gloperba® for gout flare prophylaxis [7][8]. Product Candidates - Scilex has three product candidates: - SP-102, a viscous gel for treating lumbosacral radicular pain, which has completed Phase 3 studies and received Fast Track status from the FDA [8]. - SP-103, a next-generation lidocaine topical system for acute pain, which has completed Phase 2 trials and also received Fast Track status [8]. - SP-104, a low-dose naltrexone hydrochloride for fibromyalgia treatment [8]. Datavault AI Overview - Datavault AI is focused on AI-driven data experiences and monetization of assets, providing solutions across various industries including sports, entertainment, and healthcare [10][11]. - The company’s technology suite includes patented technologies for audio transmission and high-performance computing solutions for data perception and monetization [10]. Event Details - The Dream Bowl event will take place on January 11, 2026, at AT&T Stadium in Dallas, Texas, featuring elite athletes and e-sports competitions [4].

Core Insights - Datavault AI Inc. has announced the distribution of Dream Bowl Draft meme coins to eligible shareholders of Scilex Holding Company and Datavault AI, with a record date set for November 25, 2025 [1][2][3] Company Overview - Datavault AI is a leader in data monetization, credentialing, and digital engagement technologies, focusing on AI-driven data experiences and asset valuation in the Web 3.0 environment [4] - The company offers a cloud-based platform with solutions across various industries, including sports, entertainment, biotech, education, and healthcare [4] Upcoming Events - The Dream Bowl 2026 event will feature a special distribution of commemorative meme coins to shareholders, which will include utility features such as proof of ownership and access to exclusive content [3] - Airdrop of the tokens to Data Vault wallets is expected to occur after final roster confirmations on or after December 8, 2025 [3] Shareholder Engagement - Shareholders of Datavault AI and Scilex will receive one meme coin for each common share held as of the record date, promoting shareholder value creation and engagement [2][3] - Short sellers of DVLT and SCLX common shares must cover their positions by the ex-dividend date to avoid becoming naked short on the meme coins [2]